文献速递外周动脉疾病

Rotarex S 联合药物涂层球囊治疗股腘动脉支架内再狭窄与闭塞的前瞻性两中心研究

Safety and Efficacy of Rotational Thrombectomy and Drug Coated Balloon Angioplasty in Patients with In Stent Re-stenosis and Occlusions: A Prospective, Two Centre Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-06-18

该前瞻性两中心研究纳入 215 例股腘动脉支架内再狭窄或闭塞(Tosaka II/III)患者,采用 Rotarex S 旋转血栓切除联合药物涂层球囊(DCB)治疗。主要终点为 12 个月免于临床驱动的靶病变血运重建(CD-TLR)和通畅率:13.0% 患者接受 CD-TLR,79.2% 维持一期通畅;无穿孔,外周栓塞 1.4%。

要点

  • Rotarex S 联合 DCB 可用于亚急性和慢性支架内再狭窄/闭塞的减容与血栓清除。
  • 12 个月 CD-TLR 为 13.0%,一期通畅率为 79.2%。
  • 无穿孔发生,外周栓塞 1.4%(3 例),均于索引手术内经导管抽吸处理。

核心结论

  • Rotarex S 血栓切除可安全用于亚急性和慢性支架内再狭窄及闭塞病变的减容和机化血栓清除。
  • 减容后追加 DCB 在该复杂患者队列中提供临床可接受的 CD-TLR 和通畅率。

研究设计与样本

  • 前瞻性、两中心研究,2017 年 1 月至 2023 年 8 月连续纳入 215 例股腘动脉支架内再狭窄或支架闭塞(Tosaka II 或 III)伴亚急性或慢性症状的患者。
  • 采用 Rotarex S(Straub Medical)旋转血栓切除联合 DCB 治疗。
  • 主要终点为 12 个月随访时免于临床驱动的靶病变血运重建(CD-TLR)和通畅率;次要手术终点为手术成功;次要安全终点为穿孔和外周栓塞。

主要发现

  • 患者中 84 例(39.1%)为间歇性跛行,79 例(36.7%)为缺血性静息痛,52 例(24.2%)为缺血性溃疡;42.8% 病例累及腘动脉。
  • 中位年龄 73.0 岁(IQR 68.0–77.0),男性 59.1%,糖尿病 44.7%;Tosaka III 病变(完全闭塞)165 例(76.7%);中位病变长度 22.0 cm(IQR 17.0–27.0)。
  • 无穿孔发生;外周栓塞 3 例(1.4%),均为亚急性表现且为支架完全闭塞,所有并发症均于索引手术内经手动导管抽吸治疗,无需外科手术或溶栓。
  • 1 年时 28 例(13.0%)接受 CD-TLR,156 例(79.2%)维持一期通畅。

临床怎么用

  • 对于股腘动脉支架内再狭窄或闭塞(Tosaka II/III)伴亚急性或慢性症状的患者,可考虑使用 Rotarex S 行减容和机化血栓清除后追加 DCB。
  • 术中需关注外周栓塞风险,尤其亚急性表现和支架完全闭塞病例;本研究中外周栓塞均经导管抽吸处理。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rotational thrombectomy using a Rotarex S device aids the removal of organised thrombus and soft atherosclerotic material in complex femoropopliteal lesions. The aim of this study was to assess the safety and efficacy of the Rotarex S device in combination with drug coated balloon (DCB) angioplasty for the treatment of in stent re-stenosis (ISR). METHODS: The Rotarex S (Straub Medical) was used in combination with DCB for the treatment of patients with lower limb ISR and stent occlusions (Tasaka II or III) who presented with subacute or chronic symptoms. Primary endpoints were freedom from clinically driven target lesion revascularisation (CD-TLR) and patency at 12 month follow up. The secondary procedural endpoint was procedural success. Secondary safety endpoints were perforation and peripheral embolisation. RESULTS: Between January 2017 and August 2023, 215 consecutive patients were enrolled, comprising 84 (39.1%) with claudication, 79 (36.7%) with ischaemic rest pain, and 52 (24.2%) with ischaemic ulcerations due to femoropopliteal lesions (popliteal artery involved in 42.8% of cases). The median patient age was 73.0 years (interquartile range [IQR] 68.0, 77.0), 59.1% were male, and 44.7% had diabetes mellitus. Tosaka III lesions (total occlusions) were present in 165 patients (76.7%). The median lesion length was 22.0 cm (IQR 17.0, 27.0). There were no perforations, whereas three (1.4%) peripheral embolisations were noted (all three with a subacute presentation and total stent occlusion). All complications were treated within the index procedure by manual catheter aspiration without requiring surgery or lysis. After one year, 28 patients (13.0%) underwent CD-TLR, whereas primary patency was maintained in 156 patients (79.2%). CONCLUSION: Rotarex S thrombectomy can be safely used for debulking and removal of organised thrombus in subacute and chronic ISR lesions and occlusions. Additional DCB after debulking provides clinically acceptable CD-TLR and patency rates in this complex patient cohort.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Andrassy M, Najam SA, Dukic D, et al. Safety and Efficacy of Rotational Thrombectomy and Drug Coated Balloon Angioplasty in Patients with In Stent Re-stenosis and Occlusions: A Prospective, Two Centre Study. Eur J Vasc Endovasc Surg. 2025. PMID: 40541653. doi:10.1016/j.ejvs.2025.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。